Jill C Smith

US Patent:

20110129413, Jun 2, 2011

Filed:

Nov 8, 2010

Appl. No.:

12/941719

Inventors:

Thomas T. Morgan - Pepperell MA, US
Brian M. Barth - Elizabethtown PA, US
James H. Adair - State College PA, US
Rahul Sharma - Baton Rouge LA, US
Mark Kester - Harrisburg PA, US
Jill P. Smith - Camp Hill PA, US
Erhan I. Altinoglu - Boston MA, US
Gail L. Matters - Hummelstown PA, US
James M. Kaiser - Harrisburg PA, US
Christopher McGovern - Harrisburg PA, US

International Classification:

A61K 51/12
C07K 14/77
C07K 16/00
C07K 2/00
C07K 7/06
A61K 49/00
A61K 47/42
A61K 47/22
A61K 49/18
A61K 9/14
B82Y 5/00
B82Y 40/00

US Classification:

424 129, 530367, 5303911, 530300, 530309, 424 96, 514773, 514788, 424 93, 424489, 977773, 977906, 977896

Abstract:

Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.

US Patent:

20170274100, Sep 28, 2017

Filed:

Oct 2, 2015

Appl. No.:

14/873805

Inventors:

- University Park PA, US
Erhan Altinoglu - Boston MA, US
Brian M. Barth - Elizabethtown PA, US
James M. Kaiser - Harrisburg PA, US
Mark Kester - Harrisburg PA, US
Gail L. Matters - Hummelstown PA, US
Christopher McGovern - Harrisburg PA, US
Thomas T. Morgan - Pepperell MA, US
Rahul Sharma - Baton Rouge LA, US
Jill P. Smith - Camp Hill PA, US

International Classification:

A61K 49/00
A61K 41/00

Abstract:

Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.